A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718303450.793491945 ◽

2014 ◽

Author(s):

Timothy Beukelman

Keyword(s):

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

JAMA ◽

10.1001/jama.271.23.1836 ◽

1994 ◽

Vol 271 (23) ◽

pp. 1836-1843 ◽

Cited By ~ 136

Author(s):

C. J. Fisher

Keyword(s):

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Sepsis Syndrome ◽

Phase Iii ◽

Study Group ◽

Double Blind ◽

Double Blind Placebo ◽

Trial Phase

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

Arthritis & Rheumatism ◽

10.1002/art.10141 ◽

2002 ◽

Vol 46 (3) ◽

pp. 614-624 ◽

Cited By ~ 403

Author(s):

Stanley Cohen ◽

Eric Hurd ◽

John Cush ◽

Michael Schiff ◽

Michael E. Weinblatt ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

Arthritis & Rheumatism ◽

10.1002/art.10578 ◽

2002 ◽

Vol 46 (11) ◽

pp. 2838-2846 ◽

Cited By ~ 136

Author(s):

George Nuki ◽

Barry Bresnihan ◽

Moraye B. Bear ◽

Dorothy McCabe ◽

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Clinical Improvement ◽

Controlled Trial ◽

Interleukin 1 ◽

Extension Phase ◽

Double Blind ◽

Double Blind Placebo ◽

The Orthokin® trial: a prospective double blind placebo-controlled randomised trial to investigate the effectiveness of autologous interleukin-1 receptor antagonist in the treatment of osteoarthritis (OA)

http://isrctn.org/> ◽

10.1186/isrctn44912979 ◽

2012 ◽

Author(s):

N.J.H. Raijmakers

Keyword(s):

Receptor Antagonist ◽

Interleukin 1 ◽

Randomised Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

Annals of the Rheumatic Diseases ◽

10.1136/ard.2007.076034 ◽

2007 ◽

Vol 67 (3) ◽

pp. 302-308 ◽

Cited By ~ 274

Author(s):

T Lequerre ◽

P Quartier ◽

D Rosellini ◽

F Alaoui ◽

M De Bandt ◽

...

Keyword(s):

Receptor Antagonist ◽

Interleukin 1 ◽

Adult Onset ◽

Still Disease ◽

Systemic Onset ◽

Anakinra Treatment

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

Annals of the Rheumatic Diseases ◽

10.1136/ard.2003.016014 ◽

2004 ◽

Vol 63 (9) ◽

pp. 1062-1068 ◽

Cited By ~ 189

Author(s):

S B Cohen

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Fatal myocarditis in a child with systemic onset juvenile idiopathic arthritis during treatment with an interleukin 1 receptor antagonist

Pediatric Rheumatology ◽

10.1186/1546-0096-10-8 ◽

2012 ◽

Vol 10 (1) ◽

Cited By ~ 9

Author(s):

Andrew S Zeft ◽

Shaji C Menon ◽

Dylan Miller

Keyword(s):

Receptor Antagonist ◽

Interleukin 1 ◽

Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, double-blind, placebo-controlled trial (ANAJIS)

Pediatric Rheumatology ◽

10.1186/1546-0096-6-s1-p27 ◽

2008 ◽

Vol 6 (S1) ◽

Cited By ~ 2

Author(s):

P Quartier ◽

F Allantaz ◽

R Cimaz ◽

P Pillet ◽

O Richer ◽

...

Keyword(s):

Gene Expression ◽

Gene Expression Profiling ◽

Expression Profiling ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1146988.604098 ◽

2009 ◽

Author(s):

Frank Pessler

Keyword(s):

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Withdrawal Phase ◽